Skip to main content

Advertisement

Table 1 Growth factor receptor antagonists consistently activated FOXO3a in sensitive breast cancer cells

From: Evaluating the evidence for targeting FOXO3a in breast cancer: a systematic review

First author (Year) Treatment Effect on FOXO3a (Activates/Inactivates) Cellular effects
Hegde (2007) [22] Lapatinib Activates in responsive cell lines; measured as Thr32 P-FOXO3a and by microarray, BT474 and SKBr3. No effect in resistant cell lines; MDA-MB-468 and T47D. Decreased expression of glyceraldehyde-3-phosphate dehydrogenase, enolase 1, pyruvate kinase and fatty acid synthase expression in BT474 and SKBr3
    Growth rate reduced in BT474 and SKBr3
Karadedou (2012) [23] Lapatinib Activates in BT474 or SKBR3 measured by FOXO3a nuclear translocation. Decreased expression of VEGF.
Real PJ (2005) [20] Trastuzumab Activates in MB231 and SUM159, primary breast effusions; measured as nuclear translocation of FOXO3a. Up-regulation of Bnip1.
    Increased sensitivity to apoptosis.
Krol (2007) [19] Gefitinib Activates in BT474 and SKBR3, but no effect in gefitinib-resistant lines MCF-7, MDA-MB-231, and MDA-MB-453. Measured as Thr32 P-FOXO3a and nuclear translocation analysis. Cell cycle arrest predominantly at the G(0)-G(1) phase and apoptosis.
McGovern (2009) [21] Gefitinib Activates in BT474 and SKBR3 but not the gefitinib-resistant lines MCF-7, MDA-MB-231, and MDA-MB-453. Measured as nuclear FOXO3a and microarray. Increase in Bim, p27 kip1